CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Confocal Laser Endomicroscopy (CLE) — Coverage Criteria

This policy governs coverage and medical necessity determination for use of confocal laser endomicroscopy (CLE) across indications (gastrointestinal and some non‑GI) for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyConfocal Laser Endomicroscopy (CLE) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDo not perform or bill confocal laser endomicroscopy for Blue Cross Blue Shield - Rhode Island members because the service is considered not covered/not medically necessary; verify member benefits before proceeding.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance for CLE

2FDA‑cleared CLE system families described

81-94%Pooled sensitivity (colorectal)

88-95%Pooled specificity (colorectal)

4‑quadrant biopsiesGuideline standard referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determination

General coverage stance

Coverage determination

Overall stance: Use of confocal laser endomicroscopy is not covered/not medically necessary as the evidence is insufficient to determine effects on net health outcomes.

Applies to Commercial Products; Medicare Advantage plans also list specific procedure codes as not covered.

The following procedure codes are explicitly identified as not covered for Medicare Advantage and not medically necessary for Commercial Products: 43206 (Esophagoscopy; flexible, transoral; with endomicroscopy [optical]), 43252 (Esophagogastroduodenoscopy, flexible, transoral; with endomicroscopy [optical]), 88375 (Optical endomicroscopic image(s), interpretation and report, real-time or referred; each endoscopic session), and 0397T (ERCP with endomicroscopy; list separately).

This policy does not enumerate additional clinical exclusions by indication; instead, coverage and benefit determinations are governed by the member's subscriber agreement / Evidence of Coverage or employer contract, which supersede this policy. For member‑specific coverage and eligibility information, providers should verify benefits via the provider call center or the member's benefit documents.

Rationale for the noncoverage determination: use of confocal laser endomicroscopy (CLE) is considered not covered / not medically necessary because the available evidence is insufficient to determine the technology's impact on net health outcomes. The policy concludes that current data do not adequately demonstrate improved patient‑level outcomes to support routine coverage.

When services are determined to be not medically necessary or otherwise non‑covered, providers must inform the member and obtain a written agreement before billing the member for the service. Providers should follow the terms of their participation agreement and the member's subscriber agreement regarding informed consent and member financial responsibility.

Coding and Billing

Not covered / Not medically necessary codesCPT | HCPCSNot Covered

43206	Esophagoscopy; flexible, transoral; with endomicroscopy (optical)
43252	Esophagogastroduodenoscopy, flexible, transoral; with endomicroscopy (optical)
88375	Optical endomicroscopic image(s), interpretation and report, real-time or referred; each endoscopic session
0397T	Endoscopic retrograde cholangiopancreatography (ERCP) with endomicroscopy (List separately in addition to code for primary procedure)

What Providers Need to Know / Do

Prior Authorization

Prior authorization is not applicable because confocal laser endomicroscopy (CLE) is not a covered / medically necessary service under this policy.

Prior Authorization

Prior authorization — verify with payer

Verify member benefits and any payer authorization requirements before scheduling services. Coverage may vary by product, group, or contract; authorization requirements (if any) should be confirmed with Blue Cross Blue Shield of Rhode Island.

Documentation Required

Benefit verification

Providers should check the member's Benefit Booklet, Evidence of Coverage, Subscriber Agreement, or employer group contract to determine whether CLE is a non-covered or not medically necessary benefit for that member.

Background and Context

Confocal laser endomicroscopy (CLE) is an in vivo microscopic imaging technique performed during endoscopy that uses a low‑power laser and confocal optics to visualize mucosal cellular structure. CLE systems are available as endoscope‑based or probe‑based devices and typically use intravenous fluorescein as contrast. The technology provides real‑time, high‑magnification views of the mucosal epithelium with the aim of characterizing lesions and guiding targeted biopsy, but has a limited field of view, constrained imaging depth, and requires specialized training for image acquisition and interpretation.

Definitions and Key Terms

inv-16: Confocal laser endomicroscopy (CLE) — concise definition of the technique and imaging approach

DefinitionConfocal laser endomicroscopy (CLE) is an in vivo microscopic imaging technique performed during endoscopy that uses a low‑power laser and confocal optics to visualize mucosal cellular structure, enabling real‑time cellular‑level assessment as an alternative or adjunct to biopsy/histology.

Imaging approachLight from a low‑power laser illuminates tissue and the same optics collect reflected light through a pinhole (confocal arrangement) to increase resolution; images are often obtained using intravenous fluorescein as a contrast agent.

Clinical intentUsed to characterize lesion cellular structure in real time for diagnosis, to target biopsies (eg, Barrett esophagus), and to potentially reduce the number of standard biopsies or histologic evaluations.

inv-17: Standard Barrett surveillance — definition of recommended surveillance biopsy protocol

Standard surveillance method

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyConfocal Laser Endomicroscopy (CLE) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Denial Risk

Coverage denial triggers — affected codes

Claims for confocal laser endomicroscopy (CLE) and the following CPT/HCPCS codes are considered not covered / not medically necessary and may be denied: 43206, 43252, 88375, 0397T. Avoid scheduling CLE for surveillance or diagnostic purposes without confirming coverage.

43206
43252
88375
0397T

Step Therapy

Step therapy / standard alternatives

Standard Barrett esophagus surveillance remains the recommended approach: 4-quadrant random biopsies every 2 cm with white-light endoscopy for patients without known dysplasia. CLE does not replace recommended surveillance protocols.

Denial Risk

Member financial responsibility and denial risk

If services are performed that are determined to be not medically necessary or non-covered, providers may be financially responsible and members may be billed only if they have been informed in writing and agreed in advance. To avoid inappropriate balance billing and member financial liability, confirm coverage and obtain any required authorizations or written agreements before providing CLE.

Note

Benefits and eligibility — contact provider call center

For any provider-specific questions or to confirm benefits for a particular member, contact the Blue Cross Blue Shield of Rhode Island provider call center.

High‑definition white‑light endoscopy with random 4‑quadrant biopsies every 2 cm in patients with Barrett esophagus who do not have known dysplasia.

Surveillance intervalEndoscopic surveillance every 3 to 5 years for patients with Barrett esophagus without dysplasia (per referenced guideline).

Intended purposeRandom 4‑quadrant biopsies are intended to systematically sample the Barrett mucosa to detect dysplasia that may be missed by targeted inspection alone.

inv-18: Confocal Laser Endomicroscopy (CLE) — note distinguishing probe-based and needle-based CLE modalities

Probe‑based CLE (pCLE)A fiber‑optic probe passed through the working channel of a conventional endoscope; examples include Cellvizio probe systems; depth of view ~120 μm and limited field of view, typically used for mucosal surface imaging.

Endoscope‑based CLE (eCLE)An endoscope with an integrated confocal probe at the tip (endoscope‑based system); greater depth of view (up to ~250 μm) and a limited examined area (reported up to ~700 μm in diameter).

Needle‑based CLE (nCLE)A needle‑based confocal imaging approach used during endoscopic ultrasound (EUS) to evaluate pancreatic cysts and other deeper lesions; cited in studies and meta-analyses of pancreatic applications.